Camena Bioscience develops the gSynth® platform, a TdT-free enzymatic DNA synthesis technology that enables the high-throughput production of synthetic genes of any sequence, length, and complexity. This technology addresses the limitations of traditional DNA synthesis methods, which struggle to produce long, accurate synthetic DNA at scale, thereby facilitating advancements in personalized mRNA vaccines, cell and gene therapies, and CRISPR applications.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional DNA synthesis methods struggle to produce long, accurate synthetic DNA at scale, which limits advancements in personalized mRNA vaccines, cell and gene therapies, and CRISPR applications. Current methods can be error-prone and may not meet the rising demand for complex gene-length DNA. Furthermore, existing DNA synthesis methods produce significant amounts of solvent waste, contributing to the environmental impact of the healthcare sector.
Solution
Camena Bioscience's gSynth® platform is a TdT-free enzymatic DNA synthesis technology that enables high-throughput production of synthetic genes of any sequence, length, and complexity. The gSynth® platform addresses the challenges of accuracy, length, scale, and speed in DNA synthesis. It utilizes a proprietary enzyme mix, Addamers, and a Cimban™ design algorithm to precisely synthesize kilobases of DNA in a day. The platform supports the pharmaceutical industry’s commitment to decarbonize health systems via a green synthesis technology focused on reducing waste throughout supply-chains.
Target Audience
The primary customers are pharmaceutical and biotechnology companies involved in personalized mRNA vaccines, cell and gene therapies, and CRISPR screening.
Features
- TdT-free enzymatic DNA synthesis for high accuracy
- Proprietary enzyme mix optimized for de novo DNA synthesis and gene assembly
- Addamers: A highly pure class of reagent building blocks that supports accurate DNA synthesis
- Cimban™: A proprietary bioinformatics platform and design algorithm that designs a gene path de novo
- Green chemistry: Green synthesis reagent production
- Combinatorial and parallel gene assembly approach for rapid production of complex DNA sequences
- Readily clonable double-stranded DNA output
- Universal reagent starting set, compatible with common liquid handlers